| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 12 | 2024 | 101 | 3.590 |
Why?
|
| Critical Care | 13 | 2023 | 46 | 3.030 |
Why?
|
| Intensive Care Units | 14 | 2023 | 62 | 2.350 |
Why?
|
| Critical Illness | 7 | 2020 | 42 | 2.340 |
Why?
|
| Infection Control | 4 | 2021 | 31 | 1.140 |
Why?
|
| Pandemics | 6 | 2022 | 280 | 1.130 |
Why?
|
| Humans | 52 | 2024 | 14077 | 1.130 |
Why?
|
| Shock, Septic | 5 | 2024 | 10 | 1.110 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 102 | 1.110 |
Why?
|
| Practice Guidelines as Topic | 8 | 2021 | 123 | 1.100 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 274 | 1.010 |
Why?
|
| Health Resources | 4 | 2021 | 65 | 1.010 |
Why?
|
| Fluid Therapy | 7 | 2024 | 24 | 0.990 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 70 | 0.990 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 1 | 0.800 |
Why?
|
| Inflammation | 1 | 2021 | 103 | 0.760 |
Why?
|
| Malaria | 3 | 2020 | 207 | 0.750 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 78 | 0.740 |
Why?
|
| Quality Improvement | 1 | 2020 | 32 | 0.710 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2019 | 15 | 0.580 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 41 | 0.570 |
Why?
|
| Hemoglobins | 1 | 2016 | 40 | 0.540 |
Why?
|
| Survival Rate | 2 | 2016 | 96 | 0.540 |
Why?
|
| Hospital Mortality | 1 | 2016 | 94 | 0.540 |
Why?
|
| Betacoronavirus | 3 | 2020 | 51 | 0.540 |
Why?
|
| Patient Discharge | 1 | 2016 | 27 | 0.530 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2017 | 124 | 0.520 |
Why?
|
| Hospitalization | 3 | 2021 | 392 | 0.520 |
Why?
|
| Consensus | 3 | 2021 | 59 | 0.520 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2016 | 73 | 0.510 |
Why?
|
| Antitubercular Agents | 1 | 2018 | 299 | 0.510 |
Why?
|
| Developing Countries | 4 | 2018 | 385 | 0.490 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 57 | 0.490 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2018 | 320 | 0.480 |
Why?
|
| Oxygen | 4 | 2023 | 25 | 0.460 |
Why?
|
| Tuberculosis | 1 | 2018 | 530 | 0.410 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 184 | 0.410 |
Why?
|
| Ceftriaxone | 1 | 2012 | 13 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 237 | 0.400 |
Why?
|
| Bacteria | 1 | 2012 | 46 | 0.390 |
Why?
|
| South Africa | 11 | 2021 | 7312 | 0.330 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2019 | 37 | 0.330 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 1 | 0.320 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 2 | 0.320 |
Why?
|
| Chlorhexidine | 1 | 2008 | 10 | 0.310 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 16 | 0.310 |
Why?
|
| Male | 13 | 2020 | 6489 | 0.310 |
Why?
|
| Infant, Newborn | 5 | 2019 | 1410 | 0.290 |
Why?
|
| Aged | 6 | 2020 | 1650 | 0.280 |
Why?
|
| Female | 14 | 2020 | 8751 | 0.280 |
Why?
|
| Middle Aged | 10 | 2020 | 3425 | 0.280 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2023 | 13 | 0.280 |
Why?
|
| Adult | 12 | 2023 | 5664 | 0.270 |
Why?
|
| Research Design | 3 | 2021 | 123 | 0.260 |
Why?
|
| Drug Administration Routes | 3 | 2021 | 8 | 0.260 |
Why?
|
| Infant | 5 | 2018 | 2145 | 0.260 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 153 | 0.250 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2021 | 11 | 0.240 |
Why?
|
| Delphi Technique | 2 | 2021 | 28 | 0.240 |
Why?
|
| Respiratory Insufficiency | 2 | 2021 | 17 | 0.240 |
Why?
|
| Child | 4 | 2018 | 2180 | 0.230 |
Why?
|
| Retrospective Studies | 6 | 2019 | 767 | 0.230 |
Why?
|
| Health Personnel | 2 | 2022 | 229 | 0.220 |
Why?
|
| Risk Factors | 5 | 2021 | 1431 | 0.210 |
Why?
|
| Enterobacteriaceae | 2 | 2019 | 11 | 0.210 |
Why?
|
| Resuscitation | 2 | 2021 | 18 | 0.200 |
Why?
|
| Advisory Committees | 2 | 2018 | 12 | 0.200 |
Why?
|
| Chemokines | 1 | 2021 | 9 | 0.200 |
Why?
|
| Anticoagulants | 3 | 2013 | 51 | 0.200 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 449 | 0.200 |
Why?
|
| Antimicrobial Stewardship | 2 | 2019 | 14 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 11 | 0.190 |
Why?
|
| Candidemia | 1 | 2021 | 13 | 0.190 |
Why?
|
| Erythrocyte Transfusion | 2 | 2021 | 6 | 0.190 |
Why?
|
| Cytokines | 1 | 2021 | 107 | 0.190 |
Why?
|
| Communicable Diseases | 2 | 2019 | 61 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2013 | 26 | 0.190 |
Why?
|
| Oxygenators | 1 | 2020 | 2 | 0.190 |
Why?
|
| Young Adult | 4 | 2018 | 2357 | 0.190 |
Why?
|
| Thrombosis | 1 | 2021 | 47 | 0.180 |
Why?
|
| Adolescent | 5 | 2018 | 2858 | 0.180 |
Why?
|
| Hospital Administration | 1 | 2020 | 3 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 1377 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2020 | 25 | 0.180 |
Why?
|
| Clinical Protocols | 1 | 2020 | 24 | 0.180 |
Why?
|
| Child, Preschool | 4 | 2018 | 1675 | 0.180 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2000 | 5 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2021 | 1131 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.180 |
Why?
|
| Home Care Services | 1 | 2000 | 15 | 0.180 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2019 | 19 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2019 | 3 | 0.170 |
Why?
|
| Health Priorities | 1 | 2020 | 62 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 124 | 0.170 |
Why?
|
| Neonatal Sepsis | 1 | 2019 | 26 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 243 | 0.160 |
Why?
|
| Cause of Death | 2 | 2019 | 206 | 0.160 |
Why?
|
| Expert Testimony | 1 | 2018 | 2 | 0.160 |
Why?
|
| Anti-Infective Agents | 3 | 2021 | 56 | 0.160 |
Why?
|
| Shock | 1 | 2018 | 4 | 0.160 |
Why?
|
| Chickenpox | 1 | 1998 | 2 | 0.160 |
Why?
|
| Patient Care Bundles | 1 | 2018 | 4 | 0.160 |
Why?
|
| Inservice Training | 1 | 2018 | 7 | 0.160 |
Why?
|
| Family | 1 | 2018 | 33 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 1998 | 20 | 0.160 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 3 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 4 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 18 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 20 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 37 | 0.150 |
Why?
|
| Global Health | 1 | 2019 | 183 | 0.150 |
Why?
|
| Klebsiella | 2 | 2019 | 6 | 0.140 |
Why?
|
| Escherichia coli | 2 | 2019 | 30 | 0.140 |
Why?
|
| Severe Dengue | 1 | 2016 | 1 | 0.140 |
Why?
|
| Patient Admission | 1 | 2016 | 11 | 0.140 |
Why?
|
| Blood Substitutes | 1 | 2016 | 2 | 0.140 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2016 | 2 | 0.140 |
Why?
|
| Organ Dysfunction Scores | 3 | 2021 | 3 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 210 | 0.140 |
Why?
|
| Cattle | 1 | 2016 | 27 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2018 | 97 | 0.140 |
Why?
|
| Respiration, Artificial | 3 | 2021 | 46 | 0.140 |
Why?
|
| Poverty | 1 | 2017 | 149 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2017 | 107 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 158 | 0.130 |
Why?
|
| Birth Weight | 1 | 2016 | 78 | 0.130 |
Why?
|
| Africa South of the Sahara | 1 | 2016 | 328 | 0.130 |
Why?
|
| Incidence | 2 | 2015 | 655 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 325 | 0.120 |
Why?
|
| Animals | 1 | 2016 | 1063 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 63 | 0.110 |
Why?
|
| Vena Cava Filters | 1 | 2013 | 4 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2013 | 8 | 0.110 |
Why?
|
| Cross Infection | 2 | 2006 | 49 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2013 | 20 | 0.110 |
Why?
|
| HIV Infections | 2 | 2021 | 4946 | 0.110 |
Why?
|
| Hospitals, Private | 1 | 2012 | 8 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2013 | 70 | 0.100 |
Why?
|
| Citrobacter | 1 | 2012 | 1 | 0.100 |
Why?
|
| Viridans Streptococci | 1 | 2012 | 1 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 42 | 0.100 |
Why?
|
| Immunoglobulins | 2 | 2021 | 11 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2012 | 53 | 0.100 |
Why?
|
| Electronic Health Records | 2 | 2021 | 10 | 0.100 |
Why?
|
| Reference Values | 2 | 2021 | 64 | 0.100 |
Why?
|
| Haemophilus influenzae | 1 | 2012 | 42 | 0.100 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 43 | 0.100 |
Why?
|
| Lactic Acid | 2 | 2021 | 33 | 0.100 |
Why?
|
| Time-to-Treatment | 2 | 2021 | 42 | 0.100 |
Why?
|
| Arterial Pressure | 2 | 2021 | 35 | 0.100 |
Why?
|
| Symptom Assessment | 2 | 2020 | 15 | 0.090 |
Why?
|
| Heparin | 1 | 2010 | 5 | 0.090 |
Why?
|
| Biomarkers | 2 | 2021 | 322 | 0.090 |
Why?
|
| Asthma | 1 | 2010 | 33 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 48 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2021 | 106 | 0.090 |
Why?
|
| Rwanda | 2 | 2018 | 30 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 34 | 0.080 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 265 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2018 | 95 | 0.080 |
Why?
|
| Hospitals, Special | 1 | 2007 | 4 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2007 | 10 | 0.080 |
Why?
|
| Warfarin | 1 | 2007 | 15 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2008 | 263 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 235 | 0.070 |
Why?
|
| Disease Management | 2 | 2019 | 73 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2018 | 867 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2006 | 101 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2024 | 64 | 0.060 |
Why?
|
| Income | 1 | 2024 | 83 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 6 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2021 | 8 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 6 | 0.050 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 16 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2021 | 32 | 0.050 |
Why?
|
| Dyspnea | 1 | 2021 | 9 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 4 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2021 | 11 | 0.050 |
Why?
|
| Equipment Reuse | 1 | 2020 | 2 | 0.050 |
Why?
|
| Blood Physiological Phenomena | 1 | 2020 | 3 | 0.050 |
Why?
|
| Equipment Design | 1 | 2020 | 27 | 0.050 |
Why?
|
| Partial Pressure | 1 | 2000 | 1 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2000 | 6 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2000 | 9 | 0.050 |
Why?
|
| Models, Biological | 1 | 2020 | 77 | 0.050 |
Why?
|
| Ebolavirus | 1 | 2000 | 4 | 0.040 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2000 | 9 | 0.040 |
Why?
|
| Lung | 1 | 2000 | 70 | 0.040 |
Why?
|
| Proteus mirabilis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Serratia marcescens | 1 | 2019 | 3 | 0.040 |
Why?
|
| Enterobacter cloacae | 1 | 2019 | 3 | 0.040 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 6 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 360 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2000 | 120 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2019 | 52 | 0.040 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 36 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2000 | 111 | 0.040 |
Why?
|
| Carbapenems | 1 | 2019 | 17 | 0.040 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 2 | 0.040 |
Why?
|
| Physicians | 1 | 2019 | 30 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 25 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 4 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 1998 | 3 | 0.040 |
Why?
|
| Heart Rate | 1 | 2018 | 32 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2018 | 4 | 0.040 |
Why?
|
| Body Temperature | 1 | 2018 | 7 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2018 | 11 | 0.040 |
Why?
|
| Controlled Before-After Studies | 1 | 2018 | 1 | 0.040 |
Why?
|
| Acyclovir | 1 | 1998 | 11 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 23 | 0.040 |
Why?
|
| Patient Safety | 1 | 2018 | 8 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2018 | 13 | 0.040 |
Why?
|
| Hospitals, District | 1 | 2018 | 5 | 0.040 |
Why?
|
| Length of Stay | 1 | 2018 | 43 | 0.040 |
Why?
|
| Radiography | 1 | 1998 | 80 | 0.040 |
Why?
|
| Acute Disease | 1 | 2018 | 105 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2018 | 19 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2017 | 6 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 40 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 16 | 0.040 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2018 | 27 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 230 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 61 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 271 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 1998 | 107 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2018 | 104 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 5 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2017 | 35 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2017 | 58 | 0.030 |
Why?
|
| Antimalarials | 1 | 2016 | 32 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2017 | 48 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 405 | 0.030 |
Why?
|
| Malaria, Falciparum | 1 | 2016 | 39 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 312 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 312 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 939 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1996 | 35 | 0.030 |
Why?
|
| Dabigatran | 1 | 2013 | 3 | 0.030 |
Why?
|
| beta-Alanine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 4 | 0.030 |
Why?
|
| Thiophenes | 1 | 2013 | 4 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2013 | 5 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2013 | 10 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2013 | 13 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 17 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 29 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2013 | 33 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2013 | 55 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 8 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2012 | 25 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2012 | 44 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2013 | 217 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2012 | 42 | 0.030 |
Why?
|
| Time Factors | 1 | 2013 | 503 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 250 | 0.020 |
Why?
|
| Medicine in the Arts | 1 | 2009 | 3 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 464 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1149 | 0.020 |
Why?
|
| Pregnancy | 1 | 2007 | 1815 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 21 | 0.010 |
Why?
|
| APACHE | 1 | 1996 | 12 | 0.010 |
Why?
|
| Prognosis | 1 | 1996 | 197 | 0.010 |
Why?
|